Urolithin A with immunotherapy for newly diagnosed solid tumors
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests adding a natural supplement called urolithin A to standard first-line immunotherapy for people with newly diagnosed solid tumors who have not yet had any cancer treatment. The goal is to see if it makes the immunotherapy work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a newly diagnosed solid tumor and have not received any previous cancer treatment.
- Your doctor plans to start you on immunotherapy (with or without chemo) as your first treatment.
- You are 18 years or older.
- You are generally able to take care of yourself (ECOG score 0 or 1).
- You must not have taken certain immunosuppressive drugs or mitochondrial supplements (like coenzyme Q10 or NAD+ boosters) recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (SI-B036) for people with advanced urological tumors or other solid tumors that have spread. The goal is to see if the drug is safe and effective, and it might help shrink tumors or slow their growth.
This trial tests a new drug called LY4052031 for people with advanced or metastatic cancers, especially bladder cancer. The drug aims to slow or stop tumor growth. Doctors will check if it is safe and how well it works.
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.
This trial tests an investigational drug called AWT020 for people with advanced solid tumors that have grown after standard treatment. The goal is to see if AWT020 can help shrink or control the cancer, and it might be an option for you if other treatments haven't worked or aren't suitable.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.